Abilify vs Vraylar
Side-by-side cost comparison based on Medicare Part D data
Abilify
Aripiprazole
Manufactured by Otsuka/BMS
Vraylar
Cariprazine
Manufactured by AbbVie
Abilify costs 88% less per claim than Vraylar ($45.00 vs $383.00). A generic version of Abilify is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Abilify | Vraylar |
|---|---|---|
| Avg Cost Per Claim | $45.00 | $383.00 |
| Total Medicare Spending | $567.0M | $1.7B |
| Total Beneficiaries | 1,680,000 | 486,000 |
| Total Claims | 12,480,000 | 4,320,000 |
| Annual Cost/Patient | $338.00 | $3,403.00 |
| Year-over-Year Change | -38.4% | +26.3% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Sep 17, 2029 |
| Manufacturer | Otsuka/BMS | AbbVie |
| Condition | Mental Health | Mental Health |
| Generic Name | Aripiprazole | Cariprazine |
Abilify vs Vraylar: What the Data Shows
Abilify (Aripiprazole) and Vraylar (Cariprazine) are both used to treat mental health. Based on Medicare Part D data, Abilify costs $45.00 per claim, which is 88% less than Vraylar at $383.00 per claim.
Medicare spent $567.0M on Abilify and $1.7B on Vraylar. In terms of patient reach, Abilify serves more beneficiaries (1,680,000 vs 486,000).
Year-over-year spending changed -38.4% for Abilify and +26.3% for Vraylar. Vraylar saw significant spending growth, suggesting increased utilization or price increases.
Abilify has a generic available, while Vraylar remains brand-only until its patent expires Sep 17, 2029.
Frequently Asked Questions
Abilify is cheaper at $45.00 per claim, compared to $383.00 for Vraylar. That makes Abilify about 88% less expensive per claim based on Medicare Part D data.
Yes, both Abilify and Vraylar are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Abilify has a generic version (Aripiprazole) available, which is typically much cheaper. Vraylar is currently brand-only, with patent expiring Sep 17, 2029.
Medicare Part D spent $567.0M on Abilify covering 1,680,000 beneficiaries, and $1.7B on Vraylar covering 486,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.